A Phase 2 interventional study of Eculizumab in Atypical Hemolytic-Uremic Syndrome, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome — 1 open to participants now, 1 under way, 1 of them phase 3. eculizumab · Atypical Hemolytic Uremic Syndrome.
Among the 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 5th registered.
45 studies on the registry are indexed under Atypical Hemolytic Uremic Syndrome; 14 are open to participants now.
Browse Atypical Hemolytic Uremic Syndrome studies →1 of the 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome is open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 12 Atypical Hemolytic Uremic Syndrome studies recruiting now, 10 (83%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2010.
This study's enrollment of 44 is above the median of 34 across 26 interventional studies indexed under Atypical Hemolytic Uremic Syndrome.
Median enrollment 19 across the 10 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
19 studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca: 4 open now, 5 under way, none of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 19 studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 5th registered.
AstraZeneca’s Atypical Hemolytic Uremic Syndrome studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing eculizumab in Atypical Hemolytic Uremic Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 19 in Atypical Hemolytic Uremic Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The record Primary purpose is to assess the efficacy of eculizumab in adult patients with Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and renal impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Eculizumab
All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Percentage of Patients With Complete TMA Response
Proportion of Patients with Complete TMA response was determined and defined by normalization of hematological parameters (platelet count and LDH) and preservation of renal function (defined as \< 25% increase in serum creatinine from baseline) which were sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through 26 weeks
Percentage of Patients With Modified Complete TMA Response
Proportion of Patients with Modified Complete TMA response through 26 weeks of treatment was determined and defined by normalization of hematological parameters (platelet count and LDH) and improvement in renal function (defined as ≥ 25% reduction from the baseline value in serum creatinine, which were sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through 26 weeks
Percentage of Patients With Complete Hematologic Response
Proportion of Patients with Complete Hematologic response through end of study was determined and defined by normalization of platelet count and LDH sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through 26 weeks
Percentage of Patients With Platelet Count Normalization
Proportion of Patients with Platelet Count Normalization through 26 weeks of treatment was determined and defined as the platelet count observed to be ≥ 150 x 109/L on at least two consecutive measurements which span a period of at least four weeks
Time frame: Through 26 weeks
Percentage of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement
Proportion of Patients with Estimated Glomerular Filtration Rate (eGFR) Improvement was determined and defined as an increase in eGFR by ≥ 15 mL/min/1.73m\^2 from baseline, sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through 26 weeks
Platelet Count Change From Baseline to 26 Weeks
Time frame: Through 26 weeks
Percentage of Patients With Complete TMA Response
Proportion of Patients with Complete TMA response through end of study was determined and defined by normalization of hematological parameters (platelet count and LDH) and preservation of renal function (defined as \< 25% increase in serum creatinine from baseline) which were sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through End of Study, Median Exposure 52 Weeks
Percentage of Patients With Modified Complete TMA Response
Proportion of Patients with Modified Complete TMA response through end of study was determined and defined by normalization of hematological parameters (platelet count and LDH) and improvement in renal function (defined as ≥ 25% reduction from the baseline value in serum creatinine, which were sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through End of Study, Median Exposure 52 Weeks
Percentage of Patients With Complete Hematologic Response
Proportion of Patients with Complete Hematologic response through end of study of treatment was determined and defined by normalization of platelet count and LDH sustained for at least two consecutive measurements obtained at least four weeks apart.
Time frame: Through End of Study, Median Exposure 52 Weeks
Percentage of Patients With Platelet Count Normalization
Proportion of Patients with Platelet Count Normalization through end of study of treatment was determined and defined as the platelet count observed to be ≥ 150 x 109/L on at least two consecutive measurements which span a period of at least four weeks
Time frame: Through End of Study, Median Exposure 52 Weeks
Percentage of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement
Proportion of Patients with Estimated Glomerular Filtration Rate (eGFR) Improvement was determined and defined as an increase in eGFR by ≥ 15 mL/min/1.73m\^2 from baseline sustained for at least two consecutive measurements obtained at least four weeks apart
Time frame: Through End of Study, Median Exposure 52 Weeks
Platelet Count Change From Baseline to 52 Weeks
Time frame: Through 52 Weeks
A total of 44 patients diagnosed with aHUS signed the informed consent and of these, 41 patients were treated. Three patients were excluded from the study due to failed screening procedure and did not receive eculizumab.
| Milestone | Eculizumab |
|---|---|
| Started | 44 |
| Completed | 41 |
| Not completed | 3 |
| Withdrew: Screen failure | 3 |
| Milestone | Eculizumab |
|---|---|
| Started | 41 |
| Completed | 38 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Pregnancy | 1 |
Proportion of Patients with Complete TMA response was determined and defined by normalization of hematological parameters (platelet count and LDH) and preservation of renal function (defined as \< 25% increase in serum creatinine from baseline) which were sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Complete TMA Response | 73.2 (57.1 to 85.8) |
Proportion of Patients with Modified Complete TMA response through 26 weeks of treatment was determined and defined by normalization of hematological parameters (platelet count and LDH) and improvement in renal function (defined as ≥ 25% reduction from the baseline value in serum creatinine, which were sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Modified Complete TMA Response | 56.1 (39.7 to 71.5) |
Proportion of Patients with Complete Hematologic response through end of study was determined and defined by normalization of platelet count and LDH sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Complete Hematologic Response | 87.8 (73.8 to 95.9) |
Proportion of Patients with Platelet Count Normalization through 26 weeks of treatment was determined and defined as the platelet count observed to be ≥ 150 x 109/L on at least two consecutive measurements which span a period of at least four weeks
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Platelet Count Normalization | 97.6 (87.1 to 99.9) |
Proportion of Patients with Estimated Glomerular Filtration Rate (eGFR) Improvement was determined and defined as an increase in eGFR by ≥ 15 mL/min/1.73m\^2 from baseline, sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement | 53.7 (37.4 to 69.3) |
| 10^9 cells/L | Eculizumab |
|---|---|
| Platelet Count Change From Baseline to 26 Weeks | 117.68 (92.77 to 142.59) |
Proportion of Patients with Complete TMA response through end of study was determined and defined by normalization of hematological parameters (platelet count and LDH) and preservation of renal function (defined as \< 25% increase in serum creatinine from baseline) which were sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Complete TMA Response | 80.5 (65.1 to 91.2) |
Proportion of Patients with Modified Complete TMA response through end of study was determined and defined by normalization of hematological parameters (platelet count and LDH) and improvement in renal function (defined as ≥ 25% reduction from the baseline value in serum creatinine, which were sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Modified Complete TMA Response | 63.4 (46.9 to 77.9) |
Proportion of Patients with Complete Hematologic response through end of study of treatment was determined and defined by normalization of platelet count and LDH sustained for at least two consecutive measurements obtained at least four weeks apart.
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Complete Hematologic Response | 97.6 (87.1 to 99.9) |
Proportion of Patients with Platelet Count Normalization through end of study of treatment was determined and defined as the platelet count observed to be ≥ 150 x 109/L on at least two consecutive measurements which span a period of at least four weeks
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Platelet Count Normalization | 100.0 (91.4 to 100.0) |
Proportion of Patients with Estimated Glomerular Filtration Rate (eGFR) Improvement was determined and defined as an increase in eGFR by ≥ 15 mL/min/1.73m\^2 from baseline sustained for at least two consecutive measurements obtained at least four weeks apart
| Percentage of Participants | Eculizumab |
|---|---|
| Percentage of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement | 61.0 (44.5 to 75.8) |
| 10^9 cells/L | Eculizumab |
|---|---|
| Platelet Count Change From Baseline to 52 Weeks | 102.49 (68.15 to 136.82) |
Collected over Through end of study; exposure to eculizumab in this study extended for a median duration of 11.9 months and ranged from 2.9 months to 28.8 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | — | 19/41 (46.3%) | 41/41 (100%) |
| Event | Eculizumab |
|---|---|
| Device related sepsisInfections and infestations | 2/41 |
| PyelonephritisInfections and infestations | 2/41 |
| ConvulsionNervous system disorders | 2/41 |
| Renal failure acuteRenal and urinary disorders | 2/41 |
| Renal failure chronicRenal and urinary disorders | 2/41 |
| Renal impairmentRenal and urinary disorders | 2/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/41 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 2/41 |
| Haemolytic uraemic syndromeBlood and lymphatic system disorders | 1/41 |
| Thrombotic microangiopathyBlood and lymphatic system disorders | 1/41 |
| Event | Eculizumab |
|---|---|
| HEADACHENervous system disorders | 15/41 |
| DIARRHOEAGastrointestinal disorders | 13/41 |
| OEDEMA PERIPHERALGeneral disorders | 9/41 |
| NASOPHARYNGITISInfections and infestations | 8/41 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 8/41 |
| ANAEMIABlood and lymphatic system disorders | 7/41 |
| PYREXIAGeneral disorders | 7/41 |
| URINARY TRACT INFECTIONInfections and infestations | 7/41 |
| COUGHRespiratory, thoracic and mediastinal disorders | 7/41 |
| HYPOTENSIONVascular disorders | 7/41 |
The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 41 patients who were treated with study drug were included in the ITT population.
| Age, Continuous(Years) | Eculizumab |
|---|---|
| Mean | 40.3 ± 15.33 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 28 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 38 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
The record gives a start of Jul 2010, a primary completion of Oct 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Atypical Hemolytic Uremic Syndrome →
Alexion Pharmaceuticals, Inc. →